The GEOLynch Cohort Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorWageningen University
About this trial
The GEOLynch cohort study has been established to investigate the influence of genetic, environmental and other factors on tumour risk in persons with Lynch syndrome.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene.
Aged between 18 and 80 years at inclusion.
Disqualifiers
Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP)
(Chronic) Inflammatory bowel disease
Non-Dutch speaking
Dementia or another mental condition that makes it impossible to fill out questionnaires
Trial population
Men and women aged 18 to 80 years with Lynch syndrome who do or do not have a (previous) cancer diagnosis.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
No intervention, observational study.
Other intervention
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: Persons with Lynch syndrome1 intervention
Trial outcomes
Primary outcomes
1
Colorectal tumour diagnoses
All diagnosed colorectal adenomas and carcinomas described in paticipants' medical reports and/or pathology reports.
Time frame
Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports.2
Endometrial cancer diagnoses
All diagnosed endometrial cancers described in participants' medical reports and/or pathology reports.
Time frame
Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports.3
Overall cancer diagnoses
All diagnosed cancer types described in participants' medical reports and/or pathology reports.
Time frame
Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Wageningen University
Lead sponsor
Wereld Kanker Onderzoek Fonds
Collaborator
Dutch Cancer Society
Collaborator
Funding: Biobanking and BioMolecular resources Research Infrastructure The Netherlands
Collaborator
Source ClinicalTrials.gov